Yes, Epstein-Barr virus (EBV) is a herpes virus. Its official name is human herpesvirus 4 (HHV-4), and it belongs to the gamma subfamily of the herpesvirus family. It infects roughly 95% of the global population, making it the most common and persistent human virus on the planet. Like all herpes viruses, EBV establishes a lifelong infection that can periodically reactivate.
How EBV Fits Into the Herpes Family
The herpesvirus family includes eight viruses that infect humans. Most people are familiar with herpes simplex 1 and 2 (which cause cold sores and genital herpes) and varicella-zoster (which causes chickenpox and shingles). EBV is the fourth member, grouped in the gamma subfamily alongside a less well-known relative called HHV-8, which causes Kaposi sarcoma.
What all herpes viruses share is a core behavior: once you’re infected, the virus never fully leaves your body. It goes dormant inside certain cells and can wake up later under the right conditions. For EBV specifically, the virus hides inside a type of white blood cell called B lymphocytes, where it can remain silent for decades.
How EBV Spreads and Who Gets It
EBV spreads primarily through saliva, which is why the illness it causes, infectious mononucleosis, is sometimes called “the kissing disease.” Sharing drinks, utensils, or toothbrushes can also transmit the virus. Most people get infected during childhood, when the infection typically causes no noticeable symptoms at all. When infection happens in the teens or twenties, it’s more likely to cause mono, with its hallmark fatigue, sore throat, swollen lymph nodes, and fever.
Because infection is so widespread and usually so mild in young children, most adults carry the virus without ever knowing it.
What Happens After Infection
After the initial infection clears, EBV doesn’t leave. It shifts into a dormant state called latency inside your B cells. Researchers have identified multiple latency patterns (numbered 0 through III), each defined by how many viral genes remain active. In the quietest state, latency 0, the virus expresses almost nothing, making it essentially invisible to the immune system.
Reactivation can be triggered by stress on the immune system, including other infections, immune-suppressing medications, or conditions like chronic inflammation and low oxygen in tissues. When the virus reactivates, it can produce new viral particles and shed in saliva again. Most reactivations in healthy people cause no symptoms at all, though some people report fatigue or malaise.
Diseases Linked to EBV
For most people, carrying EBV is entirely uneventful. But in a small fraction of those infected, the virus is linked to serious conditions, particularly certain cancers and autoimmune diseases.
The cancers associated with EBV include Burkitt lymphoma, classic Hodgkin lymphoma, several types of non-Hodgkin lymphoma, nasal NK-cell lymphoma, nasopharyngeal carcinoma, and a subset of gastric (stomach) cancers. These are rare outcomes relative to the billions of people carrying the virus, but the connection is well established.
On the autoimmune side, EBV has been linked to systemic lupus erythematosus, rheumatoid arthritis, and most notably multiple sclerosis (MS). A landmark study tracking more than 10 million young adults in the U.S. military found that EBV infection increased the risk of developing MS by approximately 32 times compared to those who remained uninfected. That finding, published in Science, provided the strongest evidence to date that EBV is not just associated with MS but likely a necessary trigger for the disease in most cases.
How Doctors Test for EBV
Blood tests for EBV look at different antibodies your immune system produces at different stages of infection. The pattern of these antibodies tells your doctor whether you’ve never been infected, are currently fighting a new infection, or had the virus in the past.
- Never infected: No antibodies to the viral capsid antigen (VCA) are present. This means you’re still susceptible.
- New or recent infection: A specific short-lived antibody (anti-VCA IgM) is present, but antibodies to the nuclear antigen (EBNA) have not yet appeared. EBNA antibodies take two to four months to develop after symptoms start.
- Past infection: Antibodies to both VCA and EBNA are present. This pattern can persist for life.
- Possible reactivation: Antibodies to “early antigen” (EA) can indicate active viral replication, though about 20% of healthy carriers show these antibodies even without symptoms.
EBV Vaccine Progress
There is no approved vaccine against EBV, but development is underway. Moderna has an mRNA-based vaccine candidate (mRNA-1195) in a Phase 1 clinical trial enrolling 482 participants aged 18 to 55. The trial is testing the vaccine in both people who already carry EBV and those who don’t, with estimated completion in late 2026. Given EBV’s strong connection to MS and several cancers, a successful vaccine could have a significant impact on preventing those diseases, though a widely available vaccine is still years away at the earliest.